Can a Spitz Nevus Turn Into Melanoma?

A classic Spitz nevus, as understood today, is a benign mole that does not transform into melanoma in the way most people fear. But the honest, fuller answer is messier than that reassurance suggests. Spitz nevi sit at one end of a biological spectrum that includes ambiguous “atypical Spitz tumors” in the middle and rare spitzoid melanomas at the far end, and pathologists have debated for decades where one category stops and the next begins. The practical consequence is that some lesions initially called Spitz nevi turn out, on deeper analysis, to have been something more worrisome from the start.

Why the Name Itself Causes Confusion

Sophie Spitz first described these lesions in 1948, and her original label was “juvenile melanoma.” That name stuck for years, terrifying generations of parents whose children were diagnosed with what sounded like skin cancer. Over time, researchers came to understand that the lesions were benign and could appear in all age groups, not just children.

1PubMed Central. Spitz nevi and other Spitzoid lesions part I. Background and diagnoses The renamed “Spitz nevus” reflected the consensus that these growths behave like moles, not cancers. But the old association with melanoma left a lasting shadow on the diagnosis, and the biological overlap between the two has never been fully resolved.

There is increasing evidence that spitzoid lesions may represent a distinct type of melanocytic growth, separate from both ordinary moles and conventional melanoma.

2PubMed. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, ‘Spitzoid melanoma’ and risk assessment In other words, Spitz nevi are not simply “melanomas that haven’t turned yet” or “moles that look scary.” They appear to be their own biological entity. That said, the diagnostic boundary between a Spitz nevus and a melanoma that happens to look spitzoid remains one of the most contentious questions in dermatopathology.

3PubMed. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome

The Spectrum Problem

Dermatologists and pathologists typically talk about spitzoid lesions as existing on a spectrum with three rough categories. At one end sits the classic Spitz nevus: symmetrical, well-organized under the microscope, and benign. At the other end sits spitzoid melanoma, a true cancer that just happens to share some visual features with Spitz nevi. In the murky middle sits the “atypical Spitz tumor,” a lesion that has some worrying features under the microscope but does not clearly qualify as melanoma.

The trouble is that no single microscopic feature definitively separates a Spitz nevus from melanoma. Studies have identified statistically significant differences between the two in features like how melanocytes spread within the skin, how abnormal the cells look, whether they mature as they go deeper, and whether certain protein markers stain positive.

4PubMed. Reevaluation of established and new criteria in differential diagnosis of Spitz nevus and melanoma Specific clues, such as the presence of Kamino bodies (pink, glassy globules found in the upper layers of the lesion), tend to favor a Spitz nevus diagnosis, but none of these features is individually decisive.

5PubMed Central. Spitz nevi in the classic histopathological pattern–lamb in wolf`s clothing A pathologist looking at a spitzoid lesion is weighing a constellation of features, not checking a single box.

This ambiguity means the question “can a Spitz nevus turn into melanoma?” is sometimes the wrong framing. In many disputed cases, the real issue is not that a benign lesion progressed into cancer, but that the lesion was difficult to classify correctly from the beginning.

What Genetics Reveal

Molecular research over the past decade has given pathologists something they badly needed: an objective way to tell spitzoid lesions apart from conventional melanomas. The genetic fingerprints of the two are strikingly different. Ordinary melanomas commonly carry mutations in genes like BRAF (the classic V600E variant), NRAS, or loss of NF1. Spitz tumors, by contrast, tend to carry a different set of alterations: HRAS mutations, loss of a tumor suppressor called BAP1, or fusions involving kinase genes such as ALK, ROS1, NTRK1, RET, and MET.

6PubMed Central. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy

These kinase fusions show up across the entire spitzoid spectrum. One study found them in roughly 55% of Spitz nevi, 56% of atypical Spitz tumors, and 39% of spitzoid melanomas, in a pattern where each lesion carried only one type of fusion.

7PubMed Central. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas The fact that these fusions appear throughout the spectrum, from fully benign to malignant, supports the idea that spitzoid lesions are a biologically distinct lineage. A Spitz nevus is not simply a conventional melanoma caught early; it is driven by different molecular machinery.

That said, the boundaries are not perfectly clean. Some melanomas look spitzoid under the microscope but carry classic melanoma mutations like BRAF V600K, which rules out a true Spitz melanoma diagnosis and places the lesion in the category of “spitzoid melanoma,” a conventional melanoma that happens to mimic Spitz morphology.

8PubMed Central. Gene Expression Profile of Benign, Intermediate, and Malignant Spitz and Spitzoid Melanocytic Lesions The terminology can get dizzying, but the practical takeaway is important: genetics can help distinguish a true spitzoid lesion from a melanoma masquerading as one.

BAP1-Inactivated Tumors and Inherited Risk

One genetic subgroup worth knowing about involves loss of a protein called BAP1. BAP1-inactivated melanocytic tumors share visual features with both Spitz nevi and a type of melanoma called nevoid melanoma, which makes them especially tricky to diagnose. They can occur as isolated, one-off events or as part of a hereditary syndrome in which a person carries a germline BAP1 mutation.

9PubMed. Invasive Melanoma Arising in a BAP1-Inactivated Melanocytic Tumor With NRAS Mutation: A Report of Exceptional Case With Emphasis on Its Genomic Features and Review of the Literature

People with the inherited version of BAP1 loss tend to develop multiple dome-shaped, pink or tan moles over their lifetime, sometimes dozens. These are sometimes called Wiesner nevi. While many of these lesions remain benign, the underlying germline mutation also raises the risk for other cancers, including uveal melanoma (a cancer of the eye) and mesothelioma. If a dermatologist sees a spitzoid-looking lesion that tests positive for BAP1 loss, especially in a patient with a family history of unusual cancers, genetic counseling becomes relevant. This is one scenario where a lesion in the Spitz family genuinely signals a broader cancer predisposition, even though the individual mole itself may be harmless.

Atypical Spitz Tumors and Their Surprisingly Favorable Outcomes

The middle of the spectrum, the atypical Spitz tumor, generates the most anxiety because it is the category where experts most frequently disagree. These lesions have features that make pathologists uncomfortable: perhaps the cells look more disordered than a textbook Spitz nevus, or the lesion is thicker than expected, or mitotic figures are present. Yet the clinical outcomes for patients with atypical Spitz tumors are overwhelmingly good.

A long-term follow-up study found that atypical Spitz tumors carry minimal lethal potential. They do carry a moderate risk of spreading to nearby lymph nodes, and patients with a history of atypical Spitz tumors face a somewhat increased risk of developing melanoma later in life. But the recommendation from the authors was to minimize aggressive treatment while maintaining careful surveillance.

10PubMed Central. Long-term outcome of Spitz-type melanocytic tumors

In children, the picture is even more reassuring. Pediatric spitzoid melanomas rarely develop distant spread even when cancer cells reach the lymph nodes. A review of published cases found that a large proportion of pediatric patients remained clinically well on follow-up, including several whose tumors were thick and had positive sentinel lymph nodes.

11Journal of Case Reports and Images in Pathology. Atypical Spitz nevus versus Spitz melanoma: Is age a deceiving factor? This favorable behavior in children has led some experts to argue that spitzoid lesions in kids are biologically less aggressive than adult melanomas, regardless of how alarming they look under the microscope.

The Sentinel Lymph Node Puzzle

One of the more confusing aspects of atypical Spitz tumors is that they can spread cells to nearby lymph nodes at a surprisingly high rate. A systematic review found that about 35% of atypical Spitz tumors had positive sentinel lymph node biopsies, yet overall survival ranged from 93% to 100%, and disease-free survival ranged from 87% to 100%.

12PubMed Central. Sentinel Lymph Node Biopsy in Atypical Spitz Tumor: A Systematic Review

That pattern, frequent nodal deposits but almost no deaths, is completely unlike what you see with conventional melanoma, where a positive sentinel node is a serious prognostic marker. A separate study confirmed this disconnect: sentinel lymph nodes were positive in about a quarter of atypical Spitz tumor patients and a third of spitzoid melanoma patients, yet none of 40 patients developed spread beyond the regional lymph nodes over a mean follow-up of nearly five years.

13PubMed. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors

The practical implication is significant. For conventional melanoma, finding cancer cells in a sentinel lymph node typically triggers more aggressive treatment. For atypical Spitz tumors, a positive node does not seem to carry the same ominous meaning, and some experts question whether sentinel lymph node biopsy is even useful for these lesions. Features that raise concern about a positive sentinel node in atypical Spitz tumors include a diameter over 1 cm, ulceration, deep involvement, and the presence of dividing cells.

14Journal of the American Academy of Dermatology. Spitz nevi and other Spitzoid lesions: Part II. Natural history and management

How Spitz Nevi Look and Change Over Time

If you or your child has a pigmented Spitz nevus being monitored with dermoscopy, you may notice the dermatologist tracking its changing patterns. Pigmented Spitz nevi have a well-documented life cycle when viewed under a dermatoscope. They often start with a “globular” pattern of round structures, then shift to a “starburst” pattern with streaks radiating from the edges.

15PubMed. Morphologic changes of a pigmented Spitz nevus assessed by dermoscopy

Over months to years, the starburst fades into what has been called a “stardust” pattern: the center turns gray and granular while the peripheral streaks regress, and eventually the entire lesion flattens and involutes.

16PubMed Central. Stardust Pattern as Evolution of Pigmented Spitz Nevi During Childhood This natural involution is something melanomas almost never do. A dermatologist who sees a spitzoid lesion following this predictable trajectory can gain confidence that it is behaving in a benign fashion, which sometimes spares a child an unnecessary biopsy.

Reed Nevi and Other Spitzoid Variants

Within the Spitz family, you may encounter the term “Reed nevus” or “pigmented spindle cell nevus.” These are heavily pigmented, usually very dark brown or black lesions that tend to appear on the thighs or legs of young women. Under the microscope, Reed nevi are dominated by spindle-shaped cells, while classic Spitz nevi feature larger, rounder cells sometimes called epithelioid melanocytes. In practice, the two overlap. One study found that the large, rounded “Spitz cells” were present in all classic Spitz nevi examined but also appeared in 40% of Reed nevi, making the boundary between the two somewhat artificial.

17PubMed Central. Differentiation of pigmented Spitz nevi and Reed nevi by integration of dermatopathologic and dermatoscopic findings

At the molecular level, Reed nevi frequently carry rearrangements in the NTRK3 gene, a finding seen in roughly half to 60% of these lesions. This is useful diagnostically because it helps confirm a benign spitzoid identity when the appearance alone is ambiguous.

8PubMed Central. Gene Expression Profile of Benign, Intermediate, and Malignant Spitz and Spitzoid Melanocytic Lesions

How Molecular Tests Help When the Microscope Falls Short

When a pathologist cannot confidently classify a spitzoid lesion based on its microscopic appearance alone, molecular tests can tip the balance. Two commonly used techniques look at chromosomal abnormalities. FISH uses targeted probes to detect specific gains or losses on key chromosomes, while comparative genomic hybridization scans the genome more broadly. The two methods do not always agree: some abnormalities are caught by one but not the other, and FISH has the advantage of detecting variation within different parts of the same tumor.

18Journal of Clinical and Translational Pathology. Spitz Melanoma of Childhood: A Review Compendium and Terminology Clarification

The general rule is that a single, uncommon chromosomal change may point toward an atypical Spitz tumor, while multiple gains or losses raise the suspicion for melanoma. Early molecular work showed that the specific chromosomal changes in Spitz nevi differ clearly from those found in melanoma, providing a foundation for these diagnostic tools.

19PubMed. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma

For patients, this means that if a biopsy comes back as “atypical Spitz tumor, cannot exclude melanoma,” additional molecular testing is often the next step. These tests do not always give a definitive yes-or-no answer, but they narrow the uncertainty considerably and help guide decisions about how much additional tissue needs to be removed and how closely the patient should be monitored.

What Happens After Diagnosis

Most dermatologists in the United States recommend biopsying a suspected Spitz nevus rather than just watching it. In a survey, 93% of responding dermatologists said they would biopsy a suspected Spitz nevus, and if the biopsy showed that the lesion was incompletely removed, about 69% would go back and excise the remainder.

20PubMed. Management of Spitz nevi: a survey of dermatologists in the United States Most physicians recommended excision with a narrow margin of 1 to 2 millimeters of normal-appearing skin, and pediatric dermatologists were uniformly conservative, none recommending margins wider than 4 millimeters.

For a straightforward Spitz nevus with clean margins, no further treatment is needed. For atypical Spitz tumors, re-excision with clear margins and periodic skin checks are standard. The question of whether to perform sentinel lymph node biopsy for atypical Spitz tumors is one of the more actively debated topics in the field, given the disconnect between high positivity rates and excellent survival described earlier.

When a Spitzoid Melanoma Is Confirmed

True spitzoid melanoma, a malignancy arising from or displaying spitzoid characteristics, does exist. It is rare, especially in children, but it behaves like a real cancer. When researchers compared spitzoid melanoma to conventional melanoma in adults, they found no significant differences in where the tumors appeared, how fast the cells divided, or the rate of distant spread. Mortality between the two groups was also similar.

21PubMed. Clinicopathologic features and survival in Spitzoid malignant melanoma and conventional malignant melanoma

In children, spitzoid melanoma may behave somewhat differently. One study found that children with spitzoid melanoma had worse-looking pathology features compared to children with conventional melanoma, including thicker tumors and higher rates of positive sentinel nodes. Yet the spitzoid group’s mortality rate was lower, about 6% versus 12% for conventional childhood melanoma.

22PubMed. Spitzoid and non-spitzoid melanoma in children: a prognostic comparative study The authors cautioned that the sample was small and that the selection criteria may have biased toward more aggressive cases, but the trend aligns with the broader observation that spitzoid biology in children tends to be less aggressive than expected.

The Risk of Overdiagnosis

Perhaps the most underappreciated risk in this area is not that a Spitz nevus will become melanoma, but that it will be treated as though it already is. Because the microscopic features overlap, some lesions get labeled more aggressively than they deserve, leading to wider excisions, sentinel node biopsies, and ongoing surveillance protocols that may not improve outcomes but certainly increase anxiety and cost.

23PubMed Central. Rethinking Melanocytic Tumors: A Critical Appraisal of the WHO Classification and the Myth of Nevus-to-Melanoma Progression

This is especially relevant for parents of children diagnosed with atypical Spitz tumors. The word “atypical” in a pathology report is alarming, and the possibility of melanoma naturally provokes a desire for the most aggressive treatment available. But the evidence strongly suggests that these lesions in children carry minimal risk of life-threatening progression, and overtreating them can mean unnecessary surgery and years of worry with very little clinical benefit. A thoughtful dermatologist will balance the small residual uncertainty against the real harm of overtreatment, and molecular testing increasingly helps make that call with more confidence.

Artificial Intelligence in Spitzoid Diagnosis

Given how much disagreement exists among human pathologists, researchers have begun exploring whether deep learning models can help. One effort trained an AI tool to distinguish among Spitz nevi, ordinary moles, and melanomas from digitized slide images, with the goal of integrating such a system into pathologists’ workflows for faster, more consistent readings.

24PubMed. Histologic Screening of Malignant Melanoma, Spitz, Dermal and Junctional Melanocytic Nevi Using a Deep Learning Model These tools are still in early stages and are not replacing expert pathologists, but the field’s interest in them reflects just how difficult spitzoid diagnosis remains. If AI can help reduce the rate of ambiguous calls, it could spare patients from the cascade of additional biopsies and surveillance that uncertainty triggers.